



## News Release

### **Suven Life Sciences secures Two (2) Product Patents from Japanese Patent Office (JPO) for their NCE's to treat Central Nervous System (CNS) disorders**

**HYDERABAD, INDIA (June' 16 2010)** – Suven Life Sciences Ltd (Suven) announces today that the Japanese Patent Office (JPO) has issued two product Patents: 4455992 and 4473120 to their New Chemical Entities (NCE's) which is for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid until 2022. **With these a total of 3 (three) Japanese product patents are granted to Suven.**

The granted claims of the patent include the class of **selective Serotonin receptor affinity compounds** discovered by Suven and are being developed as therapeutic agents. According to the invention 4460446 patent disclosure, the compounds are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like **Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.**

**There are several product patent applications from Suven Discovery Research are in the pipeline** and Suven secured intellectual property protection for several of their NCEs in all major markets like USA, Canada, Europe, China, Russia, India, Japan, Australia, New Zealand, Brazil and Mexico. These granted patents are exclusive intellectual property of Suven and are achieved through the internal drug discovery research efforts. **Products out of these inventions may be out-licensed at the stage of clinical Phase-1 or Phase-II.**

**"We are very pleased by the grant of these patents to Suven by Japanese Patent Office for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated \$20 billion market potential globally" says Venkat Jasti, CEO of Suven.**

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. **The Company has twelve (12) internally-discovered therapeutic drug candidates** currently in pre-clinical stage of development targeting conditions such as ADHD, Dementia, Depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.

For more information on Suven/ACT, please visit our Web site at <http://www.suven.com>

#### **Risk Statement:**

***Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;***